SANTA ROSA, Calif.--(BUSINESS WIRE)--Claret Medical™, Inc., developer of innovative solutions for cerebral protection during structural heart, vascular and cardiac surgery procedures, today announced completion of enrollment in the CLEAN-TAVI clinical trial studying its filter-based cerebral protection system (CPS). The trial was designed as a first-of-its-kind, randomized controlled trial powered to definitively demonstrate the importance of cerebral protection in reducing the number and volume of new cerebral lesions created by debris lodged in the brain as a result of transcatheter aortic valve implantation (TAVI).
The Claret Medical system is the only filter-based device on the market that both captures and removes embolic debris released during TAVI procedures that could otherwise be a source of acute stroke. The system has been safely used in more than 800 procedures worldwide to date.
Hey, check out all the research scientist jobs. Post your resume today!
